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Abstract
Multiple drug class combinations are often prescribed for the treatment of schizophrenia, although antipsychotic
monotherapy reflects FDA labeling and scientific justification for combinations is highly variable. This study was performed
to gain current data regarding drug treatment of schizophrenia as practiced in the community and to assess the frequencies
of off-label drug class combinations. 200 DSM IV-diagnosed schizophrenic patients recruited from community treatment
sources participated in this cross-sectional study of community based schizophrenic patients. Drug class categories include
First and Second Generation Antipsychotic drugs (FGA and SGA, respectively), mood stabilizers, antidepressants and anti-
anxiety drugs. 25.5% of patients received antipsychotic monotherapy; 70% of patients received an antipsychotic and
another drug class. A total of 42.5% of patients received more than one antipsychotic drug. The most common drug class
combination was antipsychotic and a mood stabilizer. Stepwise linear discriminant function analysis identified the diagnosis
of schizoaffective schizophrenia, history of having physically hurt someone and high scores on the General Portion of the
PANSS rating scale predicted the combined use of an antipsychotic drug and a mood stabilizer. ‘‘Real world’’
pharmacotherapy of schizophrenia has developed its own established practice that is predominantly off-label and may have
outstripped current data support. The economic implications for public sector payers are substantial as well as for the
revenue of the pharmaceutical industry, whose promotion of off-label drug use is an increasingly problematic. These data
are consistent with the recognition of the therapeutic limitations of both first and second generation antipsychotic drugs.
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Introduction
Off-label medication use, the clinical application of prescribed
drugs for indications other than those evaluated and approved by
the Food and Drug Administration (FDA), is widespread in many
areas of medicine[1]. Although there is considerable literature
related to the use of mood stabilizers, antidepressants and anti-
anxiety drugs added to antipsychotic drug treatment [2–17], none
of these combinations are approved by the FDA for the treatment
of schizophrenia. While off-label uses are legal and in many
instances may be in the best interest of patients, they have not
received the same degree of independent scrutiny through
randomized clinical trials as have indications approved by the
FDA. Industry sponsors may be hesitant to submit an already
approved drug for a new indication because of what may be
perceived as unnecessary expense and the considerable risk of not
meeting primary endpoints with randomized controlled trials.
Radley and co-workers [1] examined off-label prescribing patterns
of office based physicians, distinguishing treatments as having
strong or limited scientific support and found that the greatest
disparity between ‘‘supported and unsupported’’ off-label pre-
scriptions occurred among psychiatric therapies (4% strong
support vs 96% limited or no support).
Clozapine is unique among antipsychotic drugs as its indication
specifies that clozapine is ‘‘indicated for the management of
severely ill schizophrenic patients who fail to respond adequately
to standard drug treatment for schizophrenia;’’ and ‘‘for reducing
the risk of recurrent suicidal behavior in patients with schizophre-
nia or schizoaffective disorder who are judged to be at chronic risk
for re-experiencing suicidal behavior, based on history and recent
clinical state’’[18]. The unique effectiveness of clozapine contrib-
uted to the early wave of optimism regarding the therapeutic
superiority of other members of the so-called Second Generation
Antipsychotic drugs (SGA’s) [19] a notion supported in some
measure by meta-analysis.[20] Results from the recent non-
industry funded, multi-centered CATIE trial carried out in the
United States [21] and CUtLASS1trial [22] carried out in the UK,
however, have judiciously challenged the notion of superiority of
SGA over First Generation Antipsychotic Drugs (FGAs) in the
treatment of schizophrenia. In both trials, FGAs performed
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with regard to symptom reduction, side effect profile and cost
utility [21–26]. Although these findings may have been unexpect-
ed, in actuality, these studies are in substantive agreement with
FDA labeling: the effectiveness of SGAs (clozapine excluded) is no
better than FGAs for the treatment of schizophrenia.
Given the severity of schizophrenia and the limitations of the
effectiveness of antipsychotic drugs it is not surprising that
clinicians have turned to numerous empirical approaches to
enhance clinical response. We report here patterns of pharmaco-
therapy including drug class combinations used in the treatment of
seriously ill, community based schizophrenic patients. Off-label
treatments and the emerging community practice standards for the
treatment of schizophrenia are identified.
Methods
Two hundred outpatients participated in this study. Each patient
provided written informed consent for participation in the protocol
approved by Western Institutional Review Board (WIRB), Seattle
Washington and received $75 for participation. All research
procedures were carried out by Gabriel Pharma. WIRB approved
patient recruitment notices were sent to community treatment
settings, private clinicians and to the National Alliance for the
Mentally Ill in the Washington DC and Montgomery County, MD
area. Following patient self referral and initial screening by Gabriel
Pharma, each patient met with a member of the Gabriel Pharma
research team during which time the research protocol was
explained and questions were encouraged. After providing written
informed consent, he/she participated in a structured interview
detailing psychiatric, medical and drug treatment histories and
provided a venous drug collection for DNA analysis (data not
reported here). A total of 200 patients participated in the protocol
from August, 2004 through March 2006.. Participating patients
responded to recruitment notices from the following: : St Luke’s
House, Inc (25%, a private, non-profit organization that offers
integrated treatment and housing for thementally illinMontgomery
County, MD; Anchor Mental Health (23.5%), Catholic Charities’
full service community treatment center for the mentally ill in
Washington, DC; Green Door (10.5%), a private non-profit
Washington, DC community program dedicated to aiding patients
with mental illness to return to work and live independently;
National Alliance for the Mentally Ill (NAMI) (10.5%) the nation’s
largest grassroots organization for people with mental illness and
their families; Washington Assessment and Therapy Services
(WATS) (8%), a private non-profit behavioral health center in
Gaithersburg, MD that provides services for the mentally ill; DC
Department of Mental Health (4.5%), a Washington, DC
government agency that provides comprehensive mental health
services; NIH patients (9%) who had previously participated in
schizophrenia treatment protocols; Woodley House (2%), a private
non-profit program for the mentally ill that was the first community
based residential program for the mentally ill in the United States;
and Private Practice referrals (7%).
The PI (DP) administered PANSS [27] and Montgomery-
Asberg rating scales [28]; DSM IV [29] diagnosis was made by
consensus after reviewing results of the clinical interview process.
All patients had a DSM IV Axis I diagnosis of schizophrenia
(Table 1). The mean (SD) age of patients who participated in the
study was 45.1 (9.6) years and age of onset of illness was 19.9 (8.9)
of age. Nineteen per cent of patients had a BMI less than 24.9
(normal or underweight); 40% had a BME 25–29.9 (overweight);
and 41% had a BMI 30 or greater (obese). Current medications at
the time of evaluation were reported by each patient and
confirmed with notation from referring clinicians/case manager
and by medical records when available.
The classes of medications reported here were: antipsychotic
drugs (FGAs and SGAs), mood stabilizers, anti-depressants and
anti-anxiety agents. Medicationcombinations are reported as
‘‘exclusive’’ indicating that the combination is the sole treatment,
or as ‘‘non-exclusive’’ in which case other drug classes might have
also have been administered. All percentages are of the total
patient population (200) unless otherwise noted.
Linear discriminant function was applied to demographic and
rating variables shown in Tables 1 and 2 as independent variables
to predict the two most common medication class combinations:
antipsychotic and mood stabilizer; antipsychotic and antidepres-
sant as noted in the text.
Table 1. Patient Demography.
Count Percent
DSM IV DX
295.1 - Disorganized 2 1
295.3 - Paranoid 50 25
295.6 - Residual 3 1.5
295.7 - Schizoaffective 56 28
295.9 Undifferentiated 89 44
Gender
Female 81 40.5
Male 119 59.5
Race
1
African American 104 52.
Asian 6 3
Caucasian 90 45
Residence
Family Home 26 13
Non Supervised Dwelling 60 30
Shelter 5 2.5
Supervised Dwelling 109 54.5
Marital Status
Divorced/Separated 22 11
Married 18 9
Never Married 150 75
Other 10 5
Involuntary Hospitalization/s
No 105 52.5
Yes 95 47.5
Suicide Attempt/s
No 104 52.0
Yes 96 48.0
Jail
No 103 51.5
Yes 97 48.5
Ever Hurt Someone
No 141 70.5
Yes 59 29.50
1Self-reported race classification per NIH Guidelines.
doi:10.1371/journal.pone.0003150.t001
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Table 1 presents a summary of demographic and clinical
variables and Table 2 presents the means of PANSS and
Montgomery-Asberg Depression Rating Scale and the total
number of hospitalizations. Table 3 presents the patterns of
antipsychotic drug use and Table 4 details the frequencies of all
possible medication combinations. ‘‘Non-exclusive’’ use of anti-
psychotic drugs and mood stabilizers would include the total
frequency of antipsychotic and other medication classes.
In total, antipsychotic drugs were administered to 95.5% of the
patients. SGA administration was far more prevalent than FGA
administration (88% vs. 21.5%, respectively), with the majority of
patients receiving SGA without concomitant FGA (Table 3). In
contrast, the majority of patients who received FGA also received
an SGA. Thirty per cent of the patient population were
administered more than one SGA. In total, 42.5% of patients
were treated with more than one antipsychotic drug (Table 3).
25.5% of patients were treated with antipsychotics as their sole
medication class (Table 4) and 70% were treated with an
antipsychotic plus another medication class (4.5% of patients were
antipsychotic free). More than two drug classes were used in
23.5% of patients. The most common drug class combination was
antipsychotic with mood stabilizer (25.5% exclusive; 45% non-
exclusive) followed by antipsychotic with antidepressant (19%
exclusive; 38% non-exclusive) and finally, antipsychotic with
antidepressant and anti-anxiety (2.5% exclusive; 14% non-
exclusive).
Olanzapine and risperidone were each administered to 26% of
patients; quetiapine was next most prevalent (20.5%) following by
clozapine (18%), aripiprazole (14%), ziprasidone (11%), haloper-
idol (7%), depot injections (haloperidal+fluphenazine) (5%) and
1.5% other FGA’s. Divalproex was the most common mood
stabilizer (26% of patients) followed by lithium (5.5%), topiramate
(5%), carbamazepine, gabapentin and lamatrogine each of which
was administered to 2.5% of patients. Fluoxetine, buproprion and
paroxetine were each administered to 7% of patients while
venlafaxine and escitalopram were administered to 5% of patients
and citalopram to 2.5% of patients. Clonazepam (6.5%) and
lorazepam (3.5%) were the most frequently administered anti-
anxiety agents.
Table 5 shows statistically significant results of stepwise
discriminant linear function analyses in which the clinical and
demographic variables were independent variables predicting
antipsychotic plus mood stabilizer and antipsychotic plus antide-
pressant, the combinations with the largest frequencies. Antipsy-
chotic plus mood stabilizer exposure was significantly predicted
(67% correct classification, (p,0.001) by: 1) diagnosis of
schizoaffective schizophrenia; 2) history of having hurt someone;
and 3) high scores on the General Psych Portion of the PANSS
Scale. Antipsychotic plus antidepressant use (67% correct
Table 2. Mean (SD) of Total Number of Hospitalizations and
Rating Scale scores.
Total # of Hospitalizations 7.5 (7.4)
PANSS Total 110.9 (16.5)
PANSS Positive 25.8 (5.6)
PANSS Negative 28.3 (4.5)
PANSS General Psych 56.8 (4.5)
Montgomery-Asberg Total 31 (8.23)
doi:10.1371/journal.pone.0003150.t002
Table 3. Antipsychotic Usage.
Medication
Abbreviaton Treatment Count Percent
FGA=First Generation
Antipsychotic Drug
SGA without FGA 148 74
SGA=Second Generation
Antipsychotic Drug
FGA without SGA 15 7.5
FGA+SGA 28 14
No Antipsychotic Drug 9 4.5
TOTAL 200 100
Percent of FGA administration
that also received SGA
administration
28 of 43 65
More than one SGA 60 30
More than one FGA 8 4
More than one APS 85 42.5
doi:10.1371/journal.pone.0003150.t003
Table 4. All Medication Class Combinations.
Medication Class Treatment Count Percent
AA=Anti-Anxiety No Medication 5 2.5
AD=Antidepressant AA 0 0
MS=Mood Stabilizer AD 3 1.5
APS=Anti-Psychotic MS 0 0
APS 51 25.5
AD+AA 0 0
MS+AA 0 0
MS+AD 0 0
MS+AD+AA 1 .5
APS+AA 5 2.5
APS+AD+AA 8 4
APS+AD 38 19
APS+MS 51 25.5
APS+MS+AA 8 4
APS+MS+AD 22 11
APS+MS+AD+AA 8 4
TOTAL 200 100
doi:10.1371/journal.pone.0003150.t004
Table 5. Results of Linear Discriminant Function.
Clinical Predictor APS+MS n=89 APS+AD n=76
DX F=15.69, p,.001
Total # hospitalizations F=7.48, p=.006
Ever Hurt Someone F=6.0, p=.015
Montgomery-Asberg Total F=6.7, p=.01
PANNS Gen Psych F=5.34, p=.022
doi:10.1371/journal.pone.0003150.t005
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hospitalizations and higher score on the Montgomery-Asberg
depression rating scale.
Discussion
The core finding from this study of seriously ill community
based schizophrenic patients is the predominance (70%) of off-
label medication administration with the use of antipsychotic as a
sole medication class (per FDA label) a relatively infrequent
occurrence (25.5%). Despite emerging data suggesting relative
therapeutic equivalence, SGA’s were far more frequently admin-
istered than were FGAs (88 vs 21.5%); when FGA administration
occurred it was overwhelmingly as an addition to SGAs: 65% of
FGA administration was with concomitant SGAs. This study’s
sample was clinically well characterized; demographics are is
reflective of highly symptomatic patients with schizophrenia in
midlife. For example, there was a slightly higher male prevalence
(59.5%); patients were largely never married (75%); a majority live
in supervised dwelling (54.5%); and nearly half had had
involuntary hospitalizations (47.5%), had been in jail (48.5%),
and had made a suicide attempt (48%); mean age of onset was
19.9 years. These demographies place the study population into
the mainstream of community based seriously mentally is patients
with schizophrenia The relatively high prevalence of clozapine
administration (18%) is consistent with the high severity of illness
of our population as reflected by their behavioral ratings.. The
relatively low prevalence of the Schizophrenia, Disorganized Type
is likely due to the evaluation of patients through the ‘‘window’’ of
medication treatment rather than in the drug free state. 79% of the
population was overweight or obese, reflecting one of the
numerous elements of enhanced health risk that most of these
patients face. The most frequent combination of drug classes was a
mood stabilizer added to an antipsychotic drug, followed by more
than one antipsychotic, antipsychotic and antidepressant and
antipsychotic and anti-anxiety combinations. The most commonly
used APS were olanzapine (26%), and risperidone and quetiepine
(20.5%) with frequency of clozapine administration at 18%.
Buchanan et al [30] reported that 50% of 344 schizophrenic
outpatients were treated with either antidepressants, anti-anxiety
or mood stabilizers concomitant with antipsychotic drugs and that
17% of patients were treated with more than one adjunctive agent.
Tapp and colleagues [5] investigated the utilization of more than 1
antipsychotic and found in a survey of a diagnostically diverse
group of schizophrenic outpatients that 13% received an FGA
added to SGA, a comparable figure to the 13.5% frequency we
observed for this combination. Baseline medication use of the
1,493 patients of the CATIE study [31] revealed a high frequency
of no antipsychotic medication (26%) and a low frequency of more
than 1 antipsychotic (5%) and antipsychotic plus mood stabilizer
(including lithium) (15%) in comparison to the prevalence of no
antipsychotic (4.5%), patients treated with more than one
antipsychotic (42.5%) and patients treated with antipsychotic plus
mood stabilizer (44.5%) in a our cohort. Our cohort of
community-based patients who were not participating in a
prospective double-blind controlled study was likely considerably
more ill than CATIE patients as reflected by mean total PANSS
score: 111616.5 in our cohort vs 75.7617.6 for CATIE.[21]
Interestingly, baseline CATIE antipsychotic plus antidepressant
(31%) and antipsychotic plus anti-anxiety (18%) treatment
combinations 31) were comparable to prevalence among our
patients (38% and 14.5%, respectively).
The predominance of off-label drug combinations speaks to the
overriding message of CATIE [21] and CUtLASS 1 [22]: there
are significant limitations in ineffectiveness of all antipsychotic
drugs. There are, however, no clear standards or guidelines for the
use of off-label treatments. Our multivariate model predicting use
of antipsychotic drugs and concomitant mood stabilizers identified
the diagnosis of schizoaffective schizophrenia, history of having
hurt someone and high scores on the General Psychopathology
subscale of the PANSS (which includes items such as ‘‘uncoopera-
tiveness,’’ ‘‘lack of judgment and insight,’’ ‘‘poor impulse control,’’)
as predictors. This suggests combined antipsychotic and mood
stabilizers are used in patients with aggressive elements to their
behavior. In contrast, greater number of hospitalizations and high
Montgomery-Asberg depression ratings were predictors of con-
comitant antidepressant use, suggesting this approach in depressed
schizophrenics [32] with high risk of relapse. We are unaware of
data elsewhere related to clinical predictors of off label drug
administration.
There are two critical elements to off-label prescribing practices
related to the Food and Drug Administration: a drug approved for
marketing may be labeled, promoted and advertised by the
manufacturer for only those uses for which the drug’s safety and
effectiveness have been established by the FDA.[33–34] Industry
practices regarding promotion of uses not included in the drug label
havebecomeincreasinglyscrutinized,asexemplifiedbytheattention
and penalty to market practices that encourage off-label use of the
anticonvulsant, gabapentin.[35–36] The FDA has recently proposed
new guidelines that enable sponsors to distribute publications about
unapproved uses of approved drugs and advices. [37] Of serious
concern, however, is that the selective use of peer-reviewed literature
may not be able to satisfactorily ensure the quality of off-label
promotion [38–40], contributing to the problematic oversight of
industry’s promotional efforts. In contrast to industry whose
‘‘behavior’’ in the marketplace is at least theoretically closely
scrutinized, the clinician has considerable flexibility: if a product has
been FDA approved, a physician may choose to prescribe it for uses
or in treatment approaches or patient populations other than the
approved indication[33–34]. It is the responsibility of the manufac-
turer to gain FDA approval for adding new uses to the product label.
It is hardly surprising that a company may be hesitant or even
resistant to invest the resources and entertain the risk of unfavorable
results involved in FDA review of a new indication, given the
multibillion dollar revenues for medications whose off label use in
schizophrenia is described in this report Moreover, the impact of off
label use in schizophrenia is particularly great on the public sector as
schizophrenic patients’ care is largely supported by Medicaid and to
a lesser degree Medicaire. In a recent Wall Street Journal/Harris
poll [41], the public appears evenly divided on whether physicians
should (45%) or should not (46%) be allowed to prescribe
medications for off-label uses; in contrast, a majority (62%) of
respondents believe that pharmaceutical companies should not be
allowed to encourage off-label use.
Thescientificmeritsunderlyingtheuseoftheseoff-labeldrugclass
combinations are variable; although it is an area where clinicians
play a major role in the development of drug treatment[42] Radley
et al [1] used the DRUGDEX [43] system, a highly recognized
scientific documentation resource, to categorize off-label uses as
having strong scientific support, limited scientific support or no
scientific support. Their findings that 96% of psychiatric off-label
uses have limited or no support might well be questioned by the
psychiatric research community. The need for systematic evaluation
of treatment efficacy of drug class combinations is clearly needed.
In summary, there is a predominance of off-label prescription
use in the treatment of seriously ill patients with schizophrenia in
the community. It appears that the real world pharmacotherapy of
schizophrenia has developed its own established practice that may
Treatment of Schizophrenia
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of off label use in schizophrenia for public sector payers as well as
for the pharmaceutical industry are substantial. The independent
research community could make an important contribution by
supporting a program of systematic evaluation. What might such an
undertaking look like from the perspective of clinical trial design?
One clear and logical approach is to study the superiority, on some
primary endpoint (e.g.total PANSS score) when thedrug inquestion
is added to an antipsychotic in comparison with antipsychotic
monotherapy. In light of the very high drop out rate of the ambitious
CATIE study, a design that enabled a high rate of subject
completion (CATIE completion rate: 26%) would certainly be
necessaryforthe studytohavethenecessaryimpact.It’sunlikelythat
such work will stem from industry sponsored initiatives.
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